Listed

CytomX Therapeutics, Inc.

CTMXNasdaqCIK 1501989HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$1.4mRevenue, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$1.4mRevenue, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure−92.4% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−1677.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$23.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure−1670.2 pts on a year earlier
  • Net margin−1457.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$20.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure−1456.6 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow−$18.1mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Report this figure−14.5% on a year earlier

Last eight quarters

Full statements
Revenue$1.4mOperating margin −1677.1%
Free cash flow−$18.1m, Q2 FY2026
CytomX Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m33.4Revenue, Q3 FY2024, three months to 2024-09-30$33.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure38.1Revenue, Q4 FY2024, three months to 2024-12-31$38.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure50.9Revenue, Q1 FY2025, three months to 2025-03-31$50.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure18.7Revenue, Q2 FY2025, three months to 2025-06-30$18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure6.0Revenue, Q3 FY2025, three months to 2025-09-30$6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure0.7Revenue, Q4 FY2025, three months to 2025-12-31$663.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure10.3Revenue, Q1 FY2026, three months to 2026-03-31$10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure1.4Revenue, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%12.3%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Revenue: $33.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure46.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $17.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Revenue: $38.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure44.4%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $22.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Revenue: $50.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(6.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure(264.4%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure(4213.0%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$27.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Revenue: $663.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure(191.8%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$19.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Revenue: $10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(1677.1%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$23.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure
Net margin%17.2%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $5.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Revenue: $33.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure49.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Revenue: $38.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure46.2%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $23.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $50.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(0.8%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$154.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure(238.6%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$14.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269477.Report this figure(3998.5%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$26.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Revenue: $663.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure(177.9%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $10.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(1457.4%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$20.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337950.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(20.7)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$20.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269477. Derived: 9-month figure less the 6-month figure.Capital expenditure: $19.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269477. Derived: 9-month figure less the 6-month figure.Report this figure(20.0)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Capital expenditure: $80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure(21.2)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$21.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Capital expenditure: $119.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(15.8)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Capital expenditure: $27.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Report this figure(15.7)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$15.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269477. Derived: 9-month figure less the 6-month figure.Capital expenditure: −$127.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269477. Derived: 9-month figure less the 6-month figure.Report this figure(23.4)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$23.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Capital expenditure: $201.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-107146. Derived: 12-month figure less the 9-month figure.Report this figure(25.5)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$25.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211868.Report this figure(18.1)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-337950. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$76.2mOperating margin −29.3%
Free cash flow−$75.8m, FY2025
CytomX Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m37.3Revenue, FY2021, twelve months to 2021-12-31$37.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-27, accession 0000950170-23-009991.Report this figure53.2Revenue, FY2022, twelve months to 2022-12-31$53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-11, accession 0000950170-24-029191.Report this figure101Revenue, FY2023, twelve months to 2023-12-31$101.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-06, accession 0000950170-25-034575.Report this figure138Revenue, FY2024, twelve months to 2024-12-31$138.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure76.2Revenue, FY2025, twelve months to 2025-12-31$76.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(311.0%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$116.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-27, accession 0000950170-23-009991.Revenue: $37.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-27, accession 0000950170-23-009991.Report this figure(190.6%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$101.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-11, accession 0000950170-24-029191.Revenue: $53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-11, accession 0000950170-24-029191.Report this figure(6.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-06, accession 0000950170-25-034575.Revenue: $101.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-06, accession 0000950170-25-034575.Report this figure18.1%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $25.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146.Revenue: $138.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure(29.3%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$22.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146.Revenue: $76.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure
Net margin%(310.5%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$115.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-27, accession 0000950170-23-009991.Revenue: $37.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-27, accession 0000950170-23-009991.Report this figure(186.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$99.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-11, accession 0000950170-24-029191.Revenue: $53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-11, accession 0000950170-24-029191.Report this figure(0.6%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$569.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-06, accession 0000950170-25-034575.Revenue: $101.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-06, accession 0000950170-25-034575.Report this figure23.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $31.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146.Revenue: $138.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure(22.8%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$17.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107146.Revenue: $76.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(121)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$119.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-27, accession 0000950170-23-009991.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-27, accession 0000950170-23-009991.Report this figure(113)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$110.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-11, accession 0000950170-24-029191.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-11, accession 0000950170-24-029191.Report this figure(56.9)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$56.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-06, accession 0000950170-25-034575.Capital expenditure: $840.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-06, accession 0000950170-25-034575.Report this figure(86.5)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$86.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107146.Capital expenditure: $310.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure(75.8)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$75.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107146.Capital expenditure: $220.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-107146.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding CytomX Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FMR LLC2026-06-30$122.7m32,714,937Added+759,300
Kynam Capital Management, LP2026-06-30$81.4m21,703,093Added+6,690,000
BlackRock, Inc.2026-06-30$65.8m17,559,822Added+12,331,542
BANK OF AMERICA CORP /DE/2026-06-30$56.6m15,082,617Added+4,879,832
STATE STREET CORP2026-06-30$44.1m11,747,236Added+6,083,828
PERCEPTIVE ADVISORS LLC2026-06-30$39.1m10,439,185Added+340,361
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$32.0m8,525,457Reduced−207,661
Point72 Asset Management, L.P.2026-06-30$29.3m7,811,033Reduced−64,357
WELLINGTON MANAGEMENT GROUP LLP2026-06-30$19.4m5,168,961Added+1,585,976
Venrock Adviser, LLC2026-06-30$18.7m4,982,124Reduced−5,000,000

Recent filings

All 792 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

CytomX Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0620:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-338009
2026-08-0620:05 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-337950
2026-07-2712:05 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-316929
2026-06-2220:52 ET8-K5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-277631
2026-06-0320:15 ET8-K1.01 Entry into a material agreement0001193125-26-255467
2026-05-0720:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-211920
2026-05-0720:06 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-211868
2026-04-3020:16 ETDEF 14AProxy statementPeriod 2026-06-170001140361-26-018237
2026-03-1920:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-115958
2026-03-1611:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-107152

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 16, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1501989
Tickers
CTMX
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.